<DOC>
	<DOCNO>NCT00001341</DOCNO>
	<brief_summary>Thymidylate synthase ( TS ) , enzyme act utilize 5,10-CH ( 2 ) FH ( 4 ) reductive methylation deoxyuridylate ( dUMP ) , require de novo synthesis thymidylate potential chemotherapeutic target . ZD1694 new quinazolone folate analog directly inhibit TS . This phase I trial pharmacokinetic study describe define toxicity , determine MTD , describe plasma pharmacokinetics ZD1694 pediatric patient refractory cancer . The start dose trial 2.0 mg/m ( 2 ) administer 15 minute IV infusion every 21 day .</brief_summary>
	<brief_title>A Phase I Trial ZD1694 ( TOMUDEX ) , Inhibitor Thymidylate Synthase , Pediatric Patients With Advanced Neoplastic Disease</brief_title>
	<detailed_description>Thymidylate synthase ( TS ) , enzyme act utilize 5,10-CH ( 2 ) FH ( 4 ) reductive methylation deoxyuridylate ( dUMP ) , require de novo synthesis thymidylate potential chemotherapeutic target . ZD1694 new quinazolone folate analog directly inhibit TS . This phase I trial pharmacokinetic study describe define toxicity , determine MTD , describe plasma pharmacokinetics ZD1694 pediatric patient refractory cancer . The start dose trial 2.0 mg/m ( 2 ) administer 15 minute IV infusion every 21 day .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Raltitrexed</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven malignancy consider refractory standard therapy . Objective evidence progression prior therapy require . No leukemia . Bone marrow involvement tumor acceptable . Marrow biopsy require history involvement peripheral count inadequate . PRIOR/CONCURRENT THERAPY : Biologic Therapy : Recovery toxic effect prior immunotherapy require . Chemotherapy : No 2 prior chemotherapy regimen recover . At least 2 week since myelosuppressive therapy ( 6 week since nitrosoureas ) . Endocrine Therapy : Not specify . Radiotherapy : No prior central axis irradiation ( i.e. , skull , spine , rib , pelvis ) . Recovery toxic effect prior radiotherapy require . Surgery : Not specify . Other : No prior bone marrow transplantation . PATIENT CHARACTERISTICS : Age : 21 . Performance status : ECOG 02 . Life expectancy : At least 8 week . Hematopoietic : ( unless histologic evidence bone marrow involvement tumor ) . AGC least 1,500/mm3 . Platelet count least 100,000/mm3 . Hemoglobin least 8.0 g/dL . Prior transfusion acceptable . Hepatic : Bilirubin great 2 time normal . ALT great 2 time normal . Renal : Creatinine le 1.5 mg/dL OR Creatinine clearance great 60 mL/min/1.73 sqm . Cardiovascular : Not specify . Pulmonary : Not specify . OTHER : No significant accumulation third space fluid . No significant systemic illness ( e.g. , infection ) . No pregnant nursing woman . Pregnancy test require fertile woman . All patient guardian must sign informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2000</verification_date>
	<keyword>Antifolate</keyword>
	<keyword>Inhibitor</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Thymidylate Synthetase</keyword>
	<keyword>Toxicity</keyword>
</DOC>